1. Home
  2. CYTK vs ABVX Comparison

CYTK vs ABVX Comparison

Compare CYTK & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$63.42

Market Cap

7.6B

Sector

Health Care

ML Signal

HOLD

Logo Abivax SA American

ABVX

Abivax SA American

HOLD

Current Price

$114.75

Market Cap

10.5B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYTK
ABVX
Founded
1997
2013
Country
United States
France
Employees
N/A
67
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.6B
10.5B
IPO Year
2004
N/A

Fundamental Metrics

Financial Performance
Metric
CYTK
ABVX
Price
$63.42
$114.75
Analyst Decision
Strong Buy
Buy
Analyst Count
18
12
Target Price
$87.56
$128.42
AVG Volume (30 Days)
1.7M
711.6K
Earning Date
05-25-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$13,368,000.00
N/A
Revenue This Year
$9.79
N/A
Revenue Next Year
$302.66
$0.22
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$29.31
$4.77
52 Week High
$70.98
$148.83

Technical Indicators

Market Signals
Indicator
CYTK
ABVX
Relative Strength Index (RSI) 50.87 47.37
Support Level $59.25 $106.37
Resistance Level $65.93 $131.27
Average True Range (ATR) 2.54 4.85
MACD -0.34 -1.26
Stochastic Oscillator 42.07 38.42

Price Performance

Historical Comparison
CYTK
ABVX

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Share on Social Networks: